Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Blood Advances
|
August 20, 2024
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
Vincent Camus, Roch Houot, Gabriel Brisou, et al.
Blood Advances
|
May 12, 2026
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma
Pierre Decazes, Cedric Rossi, Pierre Sesques, et al.
Blood Advances
|
September 18, 2024
Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE
Vincent Camus, Mathieu Viennot, Pierre-Julien Viailly, et al.
Nature Medicine
|
September 22, 2022
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, et al.
American Journal of Hematology
|
August 4, 2020
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Pierre Sesques, Emmanuelle Ferrant, Violaine Safar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2015
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Ryan D Morin, Sarit Assouline, Miguel Alcaide, et al.
Leukemia
|
November 9, 2021
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne Mea Spanjaart, Per Ljungman, Rafael de La Camara, et al.
Journal of Hematology & Oncology
|
October 29, 2024
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
Gloria Iacoboni, Víctor Navarro, Pierre Sesques, et al.
Hemasphere
|
May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
Pierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
Journal of Hematology & Oncology
|
August 6, 2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Pierre Sesques, Amy A Kirkwood, Mi Kwon, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Blood Advances
|
August 20, 2024
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
Vincent Camus, Roch Houot, Gabriel Brisou, et al.
Blood Advances
|
May 12, 2026
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma
Pierre Decazes, Cedric Rossi, Pierre Sesques, et al.
Blood Advances
|
September 18, 2024
Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE
Vincent Camus, Mathieu Viennot, Pierre-Julien Viailly, et al.
Nature Medicine
|
September 22, 2022
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, et al.
American Journal of Hematology
|
August 4, 2020
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Pierre Sesques, Emmanuelle Ferrant, Violaine Safar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 2015
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Ryan D Morin, Sarit Assouline, Miguel Alcaide, et al.
Leukemia
|
November 9, 2021
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne Mea Spanjaart, Per Ljungman, Rafael de La Camara, et al.
Journal of Hematology & Oncology
|
October 29, 2024
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
Gloria Iacoboni, Víctor Navarro, Pierre Sesques, et al.
Hemasphere
|
May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
Pierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
Journal of Hematology & Oncology
|
August 6, 2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Pierre Sesques, Amy A Kirkwood, Mi Kwon, et al.
Page
of 7